ArticleBone marrow transplantation2026
Non-gene-edited, CD19-targeted, allogeneic CAR-T cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia: an open-label, single-arm phase 1 study.
Chenxue Wu, Lei Xue, Miaomiao Wu, Sujun Li, Qianwen Xu, Kaichun Liu, Hui Li, Hui Xu, Liyun Yang, Tao Wang and 2 more
Abstract readClinical Trial, Phase I
In one paragraphArticle in Bone marrow transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Chenxue Wu *Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.ORCID http://orcid.org/0009-0008-3767-0071 Lei Xue *Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.ORCID http://orcid.org/0000-0002-2821-9376 Miaomiao Wu *Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.ORCID http://orcid.org/0009-0003-0307-6203 Sujun LiDepartment of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.ORCID http://orcid.org/0009-0000-4741-257X Qianwen XuDepartment of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.ORCID http://orcid.org/0000-0002-6198-0829 Kaichun LiuFundamenta Therapeutics, Ltd., Suzhou, Jiangsu Province, China.
Hui LiDepartment of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.ORCID http://orcid.org/0009-0008-5594-0303 Hui XuDepartment of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Liyun YangFundamenta Therapeutics, Ltd., Suzhou, Jiangsu Province, China.
Tao WangFundamenta Therapeutics, Ltd., Suzhou, Jiangsu Province, China.
Rong JinFundamenta Therapeutics, Ltd., Suzhou, Jiangsu Province, China.
Xingbing WangDepartment of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China. wangxingbing@ustc.edu.cn.ORCID http://orcid.org/0000-0002-5591-2168 Funding
Anhui Science and Technology Department (Department of Science and Technology of Anhui Province) 2022e07020022National Natural Science Foundation of China (National Science Foundation of China) 82170221
6 · The paper itselfAbstract
Autologous chimeric antigen receptor (CAR)-T cell therapy is effective in relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), but its clinical application is restricted by manufacturing failures, high costs, and limited accessibility. Gene-edited allogeneic CAR-T cells offer an off-the-shelf alternative, yet concerns remain regarding genomic instability and graft-versus-host disease (GVHD). We conducted a phase 1 study to assess the safety and efficacy of ThisCAR-T, a non-gene-edited, CD19-directed allogeneic CAR-T cell product, in patients with R/R B-ALL. Eleven patients were treated with escalating doses of ThisCAR-T at 1 × 10
Indexed as
Antigens, CD19Immunotherapy, AdoptivePrecursor B-Cell Lymphoblastic Leukemia-LymphomaReceptors, Chimeric AntigenAdolescentAdultFemaleHumansMaleMiddle AgedRecurrenceYoung AdultAntigens, CD19Receptors, Chimeric Antigen
What OpenQuestion holds
Textmetadata
Read underepoch 390